MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Axsome Therapeutics Inc

Gesloten

SectorGezondheidszorg

118.79 0.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

116.99

Max

119.98

Belangrijke statistieken

By Trading Economics

Inkomsten

11M

-48M

Verkoop

29M

150M

Winstmarge

-31.973

Werknemers

846

EBITDA

20M

-37M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+44.25% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

678M

6B

Vorige openingsprijs

118.62

Vorige sluitingsprijs

118.79

Nieuwssentiment

By Acuity

69%

31%

352 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Axsome Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 okt 2025, 20:45 UTC

Winsten

Costco Wholesale Sales Climb in September, Early October

8 okt 2025, 20:12 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 okt 2025, 16:39 UTC

Belangrijke Marktbewegers

Mining Shares Rise as Gold Prices Soar

8 okt 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

8 okt 2025, 23:43 UTC

Marktinformatie

Gold Falls on Possible Profit-Taking -- Market Talk

8 okt 2025, 23:18 UTC

Acquisities, Fusies, Overnames

JD Logistics to Finance Acquisition Using Internal Funds

8 okt 2025, 23:17 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 okt 2025, 23:16 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 okt 2025, 21:54 UTC

Marktinformatie
Winsten

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 okt 2025, 21:30 UTC

Marktinformatie

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 okt 2025, 21:26 UTC

Marktinformatie
Winsten

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 19:15 UTC

Marktinformatie

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 okt 2025, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 okt 2025, 18:47 UTC

Marktinformatie

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Will Remain a Publicly Traded Co >TASK

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 okt 2025, 18:07 UTC

Marktinformatie

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 okt 2025, 15:57 UTC

Marktinformatie

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 okt 2025, 15:56 UTC

Marktinformatie

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 okt 2025, 15:53 UTC

Marktinformatie

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 okt 2025, 15:43 UTC

Acquisities, Fusies, Overnames

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 okt 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Vergelijking

Prijswijziging

Axsome Therapeutics Inc Prognose

Koersdoel

By TipRanks

44.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 171.14 USD  44.25%

Hoogste 200 USD

Laagste 144 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Axsome Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technische score

By Trading Central

107.24 / 112.29Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

352 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat